Development of CG923308 (CDK2/Cyclin E degrader) for solid tumors
A Cullgen novel drug discovery program focused on the nonclinical development of CG923308, a dual degrader targeting CDK2 and Cyclin E, and preparations for IND applications in the United States and China.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.